Adeona Clinical Laboratory

Adeona is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. Adeona is developing, or has partnered the development of, product candidates to treat pulmonary arterial hypertension (PAH), relapses in multiple sclerosis, cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis (ALS).

recent press releases

1.19.2012 – Adeona Announces Initiation of Phase II Clinical Trial of Trimesta™ for Cognitive Dysfunction in Multiple Sclerosis

12.21.2011 – Adeona Announces Proposed Name Change to Synthetic Biologics, Inc., and Appointment of John Monahan, Ph.D., as Senior Vice President of Research & Development

11.30.2011 – Positive Clinical Study Results Reported by Adeona's Oral Zinc for ALS Collaborator

11.14.2011 – Adeona 3rd Quarter 2011 Investor Conference Call

events

11.14.2011 – Adeona 3rd Quarter 2011 Investor Conference Call

in the news

11.2.2011 – Crain's Detroit Business
Adeona Pharmaceuticals Board Member Jeff Riley Adds Chairman’s Title

9.6.2011 – New York Times
Adjusting, More M.D.’s Add M.B.A.